News about handicap and chronic illness

MS-treatment approved

Tuesday, January 28. 2020

The European Medicines Agency (EMA) has granted a licence for the drug Siponimod (brand name: Mayzent) to be used to treat some adults with secondary progressive MS.

This is the first oral treatment in Europe that is approved to treat secondary progressive MS.

Siponimod was licensed by the US Food and Drug Administration in the United States in March 2019.

Read the article